- Home
- LEXX vs DYAI Comparison
LEXX vs DYAI Comparison
Compare LEXX & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- DYAI
- Stock Information
- Founded
- LEXX 2004
- DYAI 1979
- Country
- LEXX Canada
- DYAI United States
- Employees
- LEXX N/A
- DYAI N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEXX Health Care
- DYAI Health Care
- Exchange
- LEXX Nasdaq
- DYAI Nasdaq
- Market Cap
- LEXX 38.9M
- DYAI 31.5M
- IPO Year
- LEXX N/A
- DYAI 2004
- Fundamental
- Price
- LEXX $2.23
- DYAI $1.75
- Analyst Decision
- LEXX Strong Buy
- DYAI Strong Buy
- Analyst Count
- LEXX 2
- DYAI 1
- Target Price
- LEXX $11.00
- DYAI $6.00
- AVG Volume (30 Days)
- LEXX 202.7K
- DYAI 112.0K
- Earning Date
- LEXX 01-10-2025
- DYAI 11-12-2024
- Dividend Yield
- LEXX N/A
- DYAI N/A
- EPS Growth
- LEXX N/A
- DYAI N/A
- EPS
- LEXX N/A
- DYAI N/A
- Revenue
- LEXX $464,278.00
- DYAI $3,364,548.00
- Revenue This Year
- LEXX $20.39
- DYAI $51.30
- Revenue Next Year
- LEXX $113.25
- DYAI $73.26
- P/E Ratio
- LEXX N/A
- DYAI N/A
- Revenue Growth
- LEXX 105.24
- DYAI 13.82
- 52 Week Low
- LEXX $1.20
- DYAI $0.93
- 52 Week High
- LEXX $6.85
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- LEXX 47.23
- DYAI 56.35
- Support Level
- LEXX $2.00
- DYAI $1.36
- Resistance Level
- LEXX $2.54
- DYAI $2.20
- Average True Range (ATR)
- LEXX 0.24
- DYAI 0.24
- MACD
- LEXX -0.00
- DYAI 0.00
- Stochastic Oscillator
- LEXX 27.06
- DYAI 46.43
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.